Cargando…
Sarcopenia in heart failure: a systematic review and meta‐analysis
AIMS: Sarcopenia has been found to be frequently associated with co‐morbidity among patients with heart failure (HF). However, there remain insufficient data to accurately estimate the global prevalence of sarcopenia in HF. Therefore, the purpose of this research was to conduct a systematic review a...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8006658/ https://www.ncbi.nlm.nih.gov/pubmed/33576177 http://dx.doi.org/10.1002/ehf2.13255 |
_version_ | 1783672349506142208 |
---|---|
author | Zhang, Yan Zhang, Jia Ni, Wenqing Yuan, Xueli Zhang, Hongmin Li, Ping Xu, Jian Zhao, Zhiguang |
author_facet | Zhang, Yan Zhang, Jia Ni, Wenqing Yuan, Xueli Zhang, Hongmin Li, Ping Xu, Jian Zhao, Zhiguang |
author_sort | Zhang, Yan |
collection | PubMed |
description | AIMS: Sarcopenia has been found to be frequently associated with co‐morbidity among patients with heart failure (HF). However, there remain insufficient data to accurately estimate the global prevalence of sarcopenia in HF. Therefore, the purpose of this research was to conduct a systematic review and meta‐analysis to estimate the current overall prevalence of sarcopenia in patients with HF. METHODS AND RESULTS: We searched relevant databases for studies published up to 13 July 2020, assessing sarcopenia in vpatients with HF. After careful screening, data of included articles were extracted with a predesigned Excel form. Then the pooled prevalence of sarcopenia in patients with HF was calculated using the random‐effects model. The Q test was used to assess the heterogeneity, and I (2) statistic was calculated to quantify and evaluate the heterogeneity. Subgroup analyses were conducted to determine potential sources of heterogeneity. A total of 2852 articles were initially identified, and after removing duplicate publications and applying the selection criteria, we reviewed 79 full‐text articles. Finally, 11 articles (n = 1742 patients with HF) were included in this systematic review and meta‐analysis. The pooled prevalence of sarcopenia in patients with HF was 34% [95% confidence interval (CI): 22–47%, I (2) = 96.59%] and ranged from 10% to 69%. However, substantial heterogeneity between studies (I (2) = 96.59%, P < 0.001) was observed. There was no significant heterogeneity between subgroups by sex (P = 0.803) or the method used to define sarcopenia (P = 0.307). While the heterogeneity between subgroups by population setting was statistically significant (P < 0.001), the pooled prevalence of sarcopenia was 55% (95% CI: 43–66%) for hospitalized patients with HF and 26% (95% CI: 16–37%) for ambulatory patients. CONCLUSIONS: Sarcopenia was a common condition in patients with HF, and the prevalence of hospitalized patients was higher than for ambulatory patients. Early detection of sarcopenia was therefore important in patients with HF, and it was important to implement interventions so that physical therapists or managerial dieticians can easily be introduced into clinical practice. |
format | Online Article Text |
id | pubmed-8006658 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-80066582021-04-01 Sarcopenia in heart failure: a systematic review and meta‐analysis Zhang, Yan Zhang, Jia Ni, Wenqing Yuan, Xueli Zhang, Hongmin Li, Ping Xu, Jian Zhao, Zhiguang ESC Heart Fail Reviews AIMS: Sarcopenia has been found to be frequently associated with co‐morbidity among patients with heart failure (HF). However, there remain insufficient data to accurately estimate the global prevalence of sarcopenia in HF. Therefore, the purpose of this research was to conduct a systematic review and meta‐analysis to estimate the current overall prevalence of sarcopenia in patients with HF. METHODS AND RESULTS: We searched relevant databases for studies published up to 13 July 2020, assessing sarcopenia in vpatients with HF. After careful screening, data of included articles were extracted with a predesigned Excel form. Then the pooled prevalence of sarcopenia in patients with HF was calculated using the random‐effects model. The Q test was used to assess the heterogeneity, and I (2) statistic was calculated to quantify and evaluate the heterogeneity. Subgroup analyses were conducted to determine potential sources of heterogeneity. A total of 2852 articles were initially identified, and after removing duplicate publications and applying the selection criteria, we reviewed 79 full‐text articles. Finally, 11 articles (n = 1742 patients with HF) were included in this systematic review and meta‐analysis. The pooled prevalence of sarcopenia in patients with HF was 34% [95% confidence interval (CI): 22–47%, I (2) = 96.59%] and ranged from 10% to 69%. However, substantial heterogeneity between studies (I (2) = 96.59%, P < 0.001) was observed. There was no significant heterogeneity between subgroups by sex (P = 0.803) or the method used to define sarcopenia (P = 0.307). While the heterogeneity between subgroups by population setting was statistically significant (P < 0.001), the pooled prevalence of sarcopenia was 55% (95% CI: 43–66%) for hospitalized patients with HF and 26% (95% CI: 16–37%) for ambulatory patients. CONCLUSIONS: Sarcopenia was a common condition in patients with HF, and the prevalence of hospitalized patients was higher than for ambulatory patients. Early detection of sarcopenia was therefore important in patients with HF, and it was important to implement interventions so that physical therapists or managerial dieticians can easily be introduced into clinical practice. John Wiley and Sons Inc. 2021-02-11 /pmc/articles/PMC8006658/ /pubmed/33576177 http://dx.doi.org/10.1002/ehf2.13255 Text en © 2021 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Reviews Zhang, Yan Zhang, Jia Ni, Wenqing Yuan, Xueli Zhang, Hongmin Li, Ping Xu, Jian Zhao, Zhiguang Sarcopenia in heart failure: a systematic review and meta‐analysis |
title | Sarcopenia in heart failure: a systematic review and meta‐analysis |
title_full | Sarcopenia in heart failure: a systematic review and meta‐analysis |
title_fullStr | Sarcopenia in heart failure: a systematic review and meta‐analysis |
title_full_unstemmed | Sarcopenia in heart failure: a systematic review and meta‐analysis |
title_short | Sarcopenia in heart failure: a systematic review and meta‐analysis |
title_sort | sarcopenia in heart failure: a systematic review and meta‐analysis |
topic | Reviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8006658/ https://www.ncbi.nlm.nih.gov/pubmed/33576177 http://dx.doi.org/10.1002/ehf2.13255 |
work_keys_str_mv | AT zhangyan sarcopeniainheartfailureasystematicreviewandmetaanalysis AT zhangjia sarcopeniainheartfailureasystematicreviewandmetaanalysis AT niwenqing sarcopeniainheartfailureasystematicreviewandmetaanalysis AT yuanxueli sarcopeniainheartfailureasystematicreviewandmetaanalysis AT zhanghongmin sarcopeniainheartfailureasystematicreviewandmetaanalysis AT liping sarcopeniainheartfailureasystematicreviewandmetaanalysis AT xujian sarcopeniainheartfailureasystematicreviewandmetaanalysis AT zhaozhiguang sarcopeniainheartfailureasystematicreviewandmetaanalysis |